Neuronetics, Inc. Files 8-K Report
Ticker: STIM · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1227636
| Field | Detail |
|---|---|
| Company | Neuronetics, Inc. (STIM) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
NEURONETICS FILES 8-K - STANDARD REPORTING
AI Summary
On March 25, 2024, Neuronetics, Inc. filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or significant operational updates, but rather standard reporting information.
Why It Matters
This filing indicates that Neuronetics, Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or significant negative events.
Key Players & Entities
- Neuronetics, Inc. (company) — Registrant
- March 25, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- Malvern, PA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Neuronetics, Inc.?
The primary purpose of this 8-K filing is to report an 'Other Event' as of March 25, 2024, fulfilling the company's current reporting obligations to the SEC.
When was this 8-K report filed by Neuronetics, Inc.?
This 8-K report was filed on March 25, 2024.
What is the principal executive office address for Neuronetics, Inc.?
The principal executive office address for Neuronetics, Inc. is 3222 Phoenixville Pike, Malvern, PA 19355.
In which state is Neuronetics, Inc. incorporated?
Neuronetics, Inc. is incorporated in Delaware.
Does this filing disclose any specific financial transactions or material business developments?
Based on the provided text, this filing is categorized as an 'Other Event' and does not appear to disclose specific financial transactions or material business developments beyond standard reporting information.
Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-03-25 16:59:05
Key Financial Figures
- $0.01 — nge on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M
Filing Documents
- d791913d8k.htm (8-K) — 22KB
- 0001193125-24-076600.txt ( ) — 137KB
- stim-20240325.xsd (EX-101.SCH) — 3KB
- stim-20240325_lab.xml (EX-101.LAB) — 17KB
- stim-20240325_pre.xml (EX-101.PRE) — 11KB
- d791913d8k_htm.xml (XML) — 3KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2024 NEURONETICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38546 33-1051425 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3222 Phoenixville Pike , Malvern , PA 19355 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (610) 640-4202 (Former name or former address, if changed since last report.) Not applicable. Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name on each exchange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01 Other Events. On March 25, 2024, Neuronetics, Inc. (the "Company") posted supplemental information regarding recent clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy to be used as a first-line, adjunct for the treatment of major depressive disorder in adolescent patients aged 15-21. The information is posted to the Company's website at http://ir.neuronetics.com . SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEURONETICS, INC. (Registrant) Date: March 25, 2024 By: /s/ Stephen Furlong Name: Stephen Furlong Title: EVP, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)